With many COVID-19 treatments now available, a simple blood test can show doctors the best route to take. Charlottesville’s AMPEL BioSolutions says it can predict and detect the severity of a COVID-19 infection, as well as how to help a patient through its new genomic test called CovGENE.

AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19 in patients while also determining the best treatment options for each specific case.

While the COVID pandemic is easing in some places, the CDC says it’s the third leading cause of death for the third year in a row. Now, a Virginia company says it’s got a test that will help doctors determine which patients are at greatest risk so they can prescribe the best treatment.

AMPEL BioSolutions today announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19 in patients while also determining the best treatment options for each specific case.

A genomic test being developed by a Charlottesville company can predict a patient’s risk of developing severe COVID-19, new research from UVA Health suggests. That information could help doctors identify patients at high risk for poor outcomes and quickly begin tailored treatment. 

As doctors and public health officials brace for a possible fall coronavirus surge, one of the challenges continues to be predicting who will have a mild, moderate or severe case of COVID-19.

Will I get severe ill if infected with COVID-19? This new genomic test can identify patients at high risk for poor outcomes.

CLICK TO VIEW ARTICLE > By Riley Wyant CHARLOTTESVILLE, Va. (WVIR) - The COVID-19 pandemic has presented many complex challenges to those in the medical field. One Charlottesville-based company stepped up to the plate to come up with a solution beyond just testing...

“AMPEL’s goal is to accelerate getting effective treatments to COVID patients to be able to blunt that serious illness that leads to lung damage and death,” said Dr. Amrie Grammer, Co-Founder, COO, and CSO of AMPEL BioSolutions.

Now, a simple, efficient and quick genomic blood test could be a game-changer in identifying patients who may experience a severe course of COVID and to provide decision support for the type of medical treatments that may be helpful.

What a revelation. It turns out that a person’s genes have a big influence over how or his or her immunological system responds to the COVID-19 virus. A Charlottesville company, Ampel Biosolutions, has developed a blood test, which it claims predicts with 90% accuracy if a COVID-infected patient is at risk for a serious, life-threatening case.